| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $4.1M | — | +11.6% |
| SG&A Expense | $2.2M | — | +14.1% |
| Operating Income | -$6.3M | — | -12.4% |
| Net Income | -$6.0M | — | -13.5% |
| EPS (Basic) | -$0.26 | — | +3.7% |
| EPS (Diluted) | -$0.26 | — | +3.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $25.1M | -20.6% | -15.9% |
| Current Assets | $25.4M | -19.9% | -15.8% |
| Total Assets | $25.4M | -19.9% | -15.8% |
| Current Liabilities | $11.2M | -15.9% | +21.6% |
| Total Liabilities | $11.2M | -15.9% | +21.6% |
| Stockholders' Equity | $14.2M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$6.5M | — | -56.0% |
| Investing Cash Flow | $0 | — | — |
| Financing Cash Flow | $7K | — | -100.0% |
| -32.1% |